We seek to develop a plan for amending the current Intellectual Property Rights (IPR) regime for rewarding pharmaceutical innovations. The existing IPR regime is highly problematic. This has become obvious in the wake of a series of public health emergencies, most notably the AIDS crisis, which pits the vital needs of poor patients against the need of pharmaceutical companies to recoup their inves ...